Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

Sid E. O'Bryant, Veer Gupta, Kim Henriksen, Melissa Edwards, Andreas Jeromin, Simone Lista, Chantal Bazenet, Holly Soares, Simon Lovestone, Harald Hampel, Thomas Montine, Kaj Blennow, Tatiana Foroud, Maria Carrillo, Neill Graff-Radford, Christoph Laske, Monique Breteler, Leslie Shaw, John Q. Trojanowski, Nicole SchupfRobert A. Rissman, Anne M. Fagan, Pankaj Oberoi, Robert Umek, Michael W. Weiner, Paula Grammas, Holly Posner, Ralph Martins

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.

Original languageEnglish (US)
Pages (from-to)549-560
Number of pages12
JournalAlzheimer's and Dementia
Volume11
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Alzheimer Disease
Biomarkers
Guidelines
Research
Neuroimaging
Cerebrospinal Fluid
Publications
Cohort Studies
Costs and Cost Analysis
Therapeutics

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Blood
  • Dementia
  • Diagnosis
  • Plasma
  • Serum
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. / O'Bryant, Sid E.; Gupta, Veer; Henriksen, Kim; Edwards, Melissa; Jeromin, Andreas; Lista, Simone; Bazenet, Chantal; Soares, Holly; Lovestone, Simon; Hampel, Harald; Montine, Thomas; Blennow, Kaj; Foroud, Tatiana; Carrillo, Maria; Graff-Radford, Neill; Laske, Christoph; Breteler, Monique; Shaw, Leslie; Trojanowski, John Q.; Schupf, Nicole; Rissman, Robert A.; Fagan, Anne M.; Oberoi, Pankaj; Umek, Robert; Weiner, Michael W.; Grammas, Paula; Posner, Holly; Martins, Ralph.

In: Alzheimer's and Dementia, Vol. 11, No. 5, 01.05.2015, p. 549-560.

Research output: Contribution to journalArticle

O'Bryant, SE, Gupta, V, Henriksen, K, Edwards, M, Jeromin, A, Lista, S, Bazenet, C, Soares, H, Lovestone, S, Hampel, H, Montine, T, Blennow, K, Foroud, T, Carrillo, M, Graff-Radford, N, Laske, C, Breteler, M, Shaw, L, Trojanowski, JQ, Schupf, N, Rissman, RA, Fagan, AM, Oberoi, P, Umek, R, Weiner, MW, Grammas, P, Posner, H & Martins, R 2015, 'Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research', Alzheimer's and Dementia, vol. 11, no. 5, pp. 549-560. https://doi.org/10.1016/j.jalz.2014.08.099
O'Bryant, Sid E. ; Gupta, Veer ; Henriksen, Kim ; Edwards, Melissa ; Jeromin, Andreas ; Lista, Simone ; Bazenet, Chantal ; Soares, Holly ; Lovestone, Simon ; Hampel, Harald ; Montine, Thomas ; Blennow, Kaj ; Foroud, Tatiana ; Carrillo, Maria ; Graff-Radford, Neill ; Laske, Christoph ; Breteler, Monique ; Shaw, Leslie ; Trojanowski, John Q. ; Schupf, Nicole ; Rissman, Robert A. ; Fagan, Anne M. ; Oberoi, Pankaj ; Umek, Robert ; Weiner, Michael W. ; Grammas, Paula ; Posner, Holly ; Martins, Ralph. / Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. In: Alzheimer's and Dementia. 2015 ; Vol. 11, No. 5. pp. 549-560.
@article{e2b3c2c601234692ac23660d19795d93,
title = "Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research",
abstract = "The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.",
keywords = "Alzheimer's disease, Biomarkers, Blood, Dementia, Diagnosis, Plasma, Serum, Treatment",
author = "O'Bryant, {Sid E.} and Veer Gupta and Kim Henriksen and Melissa Edwards and Andreas Jeromin and Simone Lista and Chantal Bazenet and Holly Soares and Simon Lovestone and Harald Hampel and Thomas Montine and Kaj Blennow and Tatiana Foroud and Maria Carrillo and Neill Graff-Radford and Christoph Laske and Monique Breteler and Leslie Shaw and Trojanowski, {John Q.} and Nicole Schupf and Rissman, {Robert A.} and Fagan, {Anne M.} and Pankaj Oberoi and Robert Umek and Weiner, {Michael W.} and Paula Grammas and Holly Posner and Ralph Martins",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.jalz.2014.08.099",
language = "English (US)",
volume = "11",
pages = "549--560",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

AU - O'Bryant, Sid E.

AU - Gupta, Veer

AU - Henriksen, Kim

AU - Edwards, Melissa

AU - Jeromin, Andreas

AU - Lista, Simone

AU - Bazenet, Chantal

AU - Soares, Holly

AU - Lovestone, Simon

AU - Hampel, Harald

AU - Montine, Thomas

AU - Blennow, Kaj

AU - Foroud, Tatiana

AU - Carrillo, Maria

AU - Graff-Radford, Neill

AU - Laske, Christoph

AU - Breteler, Monique

AU - Shaw, Leslie

AU - Trojanowski, John Q.

AU - Schupf, Nicole

AU - Rissman, Robert A.

AU - Fagan, Anne M.

AU - Oberoi, Pankaj

AU - Umek, Robert

AU - Weiner, Michael W.

AU - Grammas, Paula

AU - Posner, Holly

AU - Martins, Ralph

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.

AB - The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.

KW - Alzheimer's disease

KW - Biomarkers

KW - Blood

KW - Dementia

KW - Diagnosis

KW - Plasma

KW - Serum

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84929264851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929264851&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2014.08.099

DO - 10.1016/j.jalz.2014.08.099

M3 - Article

C2 - 25282381

AN - SCOPUS:84929264851

VL - 11

SP - 549

EP - 560

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 5

ER -